On October 4, 2023 Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, reported that Beyond Cancer, Ltd. will present two proffered posters at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper)-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) (Free AACR-NCI-EORTC Whitepaper) AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) 2023, which is scheduled to be held October 11th – 15th in Boston, Massachusetts (Press release, Beyond Air, OCT 4, 2023, View Source [SID1234635658]). Abstracts are scheduled to be released to AACR (Free AACR Whitepaper)-NCI-EORTC registrants today 12:00 pm U.S. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the Company’s poster presentations are as follows:

Title: Intratumoral Administration of Ultra High-Concentration Nitric Oxide (UNO) and Anti PD-1 Treatment Leads to High Tumor Regression Rates and Prolonged Survival in Tumor-Bearing Mice
Poster number: A078
Session: Poster Session A
Session Date and Time: Thursday, October 12, 2023 / 12:30 pm – 4:00 pm EDT
Session Location: Level 2, Exhibit Hall D
Abstract Number: 35782
Participant: Yana Epshtein, PhD; Head of Translational Science, Beyond Cancer, Ltd.

Title: Ultra-high concentration nitric oxide (UNO) enhances anti-CTLA-4 treatment activity and induces a durable anti-tumor response
Poster number: C080
Session: Poster Session C
Session Date and Time: Saturday, October 14, 2023 / 12:30 pm – 4:00 pm EDT
Session Location: Level 2, Exhibit Hall D
Abstract Number: 35688
Participant: Yogev Sela, PhD; Head of In Vitro Studies, Beyond Cancer, Ltd.

About Nitric Oxide
Nitric Oxide (NO) is a potent molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens.